HXBM (HXBM) Stock Price & Analysis
HXBM (HXBM) rose 0.00% to USD 1.79 as of June 10, 2026 at 00:56 UTC, according to Nexqual real-time market data.
HXBM last closed at USD 1.79; the session ranged USD 1.79–1.79 on volume of 100 shares. Market capitalization is $402,227, with a 52-week range of USD 1–6.45 (PNK). Source: Nexqual, June 10, 2026 at 00:56 UTC.
Key Statistics (as of June 10, 2026 at 00:56 UTC)
| Price | USD 1.79 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 1.79 |
| Open | USD 1.79 |
| Day Range | USD 1.79 – 1.79 |
| 52-Week Range | USD 1 – 6.45 |
| Volume | 100 shares |
| Market Cap | $402,227 |
| Exchange | PNK |
Technical Analysis (HXBM)
Nexqual's technical model rates HXBM "BUY" based on 5 bullish and 2 bearish signals across 123 daily candles, as of June 10, 2026 at 00:56 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Above (USD 1.42) |
| MACD | 0.08 (positive) |
Analyst Ratings (HXBM)
Wall Street analysts rate HXBM "None", per Nexqual as of June 10, 2026 at 00:56 UTC.
| Consensus Rating | None |
|---|
Earnings (HXBM)
Source: Nexqual, June 10, 2026 at 00:56 UTC.
Financials & Fundamentals (HXBM)
| Total Revenue | $2.07M |
|---|---|
| Revenue Growth (YoY) | +18.80% |
| Gross Margin | +68.96% |
| Operating Margin | -159.50% |
| Profit Margin | -125.06% |
| ROE | -122.53% |
| Current Ratio | 2.33 |
| Total Cash | $216,534 |
| Total Debt | $0 |
| Free Cash Flow | $-1.08M |
Source: Nexqual, June 10, 2026 at 00:56 UTC.
Financial Health Score (HXBM)
Nexqual rates HXBM's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 00:56 UTC.
| Growth | Strong — Revenue +19% YoY (latest Q) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $217K cash, no debt |
| Cash Flow | Weak — FCF negative: -$1M, burning cash |
| Efficiency | Critical — ROE -123%, ROA -59.0% |
Ownership (HXBM)
| Shares Outstanding | 224,708 |
|---|
Source: Nexqual, June 10, 2026 at 00:56 UTC.
Leadership (HXBM)
HXBM is led by Robin L. Carmichael (age 68), President, CEO & Chairman, per Nexqual as of June 10, 2026 at 00:56 UTC.
| President, CEO & Chairman | Robin L. Carmichael (age 68) |
|---|
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| HMGN | HEMAGEN DIAGNOSTICS INC | USD 0 | ▲ 0% |
| MYMX | MYMETICS CORPORATION | USD 0 | ▲ 0% |
| ERGO | Entia Biosciences Inc. | USD 0 | ▲ 0% |
| ICCC | ImmuCell Corporation | USD 9.77 | ▲ 1.66% |
| INIS | Radnostix, Inc. | USD 0.07 | ▲ 3.29% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:56 UTC. This page is informational and not investment advice.